Open a free Demat account & get ₹500 in stocks.Claim
Nifty 5023,146.152.31%H 23,149.85 · L 22,913.8as of 16 Oct, 3:31 PM IST|Sensex74,729.272.68%H 74,778.78 · L 74,012.99as of 16 Oct, 3:32 PM IST|Bank Nifty55,8440.95%H 55,989.55 · L 55,526.3as of 16 Oct, 3:31 PM IST|USD / INR₹94.950.1%H ₹95.06 · L ₹94.66as of 2:30 AM IST|Gold Intl (10g)₹1,27,807.860.4%H ₹1,28,830.51 · L ₹1,27,221.74as of 2:29 AM IST|Silver Intl (1kg)₹1,74,416.650.04%H ₹1,77,484.62 · L ₹1,74,111.38as of 2:29 AM IST|Crude WTI₹9,403.852.63%H ₹9,432.33 · L ₹9,047.79as of 2:29 AM IST|Bitcoin₹77,04,6811.28%H ₹77,53,868.39 · L ₹76,55,493.61as of 12:41 AM IST|Ethereum₹2,28,3261.58%H ₹2,30,130.19 · L ₹2,26,521.81as of 12:41 AM IST|Nifty 5023,146.152.31%H 23,149.85 · L 22,913.8as of 16 Oct, 3:31 PM IST|Sensex74,729.272.68%H 74,778.78 · L 74,012.99as of 16 Oct, 3:32 PM IST|Bank Nifty55,8440.95%H 55,989.55 · L 55,526.3as of 16 Oct, 3:31 PM IST|USD / INR₹94.950.1%H ₹95.06 · L ₹94.66as of 2:30 AM IST|Gold Intl (10g)₹1,27,807.860.4%H ₹1,28,830.51 · L ₹1,27,221.74as of 2:29 AM IST|Silver Intl (1kg)₹1,74,416.650.04%H ₹1,77,484.62 · L ₹1,74,111.38as of 2:29 AM IST|Crude WTI₹9,403.852.63%H ₹9,432.33 · L ₹9,047.79as of 2:29 AM IST|Bitcoin₹77,04,6811.28%H ₹77,53,868.39 · L ₹76,55,493.61as of 12:41 AM IST|Ethereum₹2,28,3261.58%H ₹2,30,130.19 · L ₹2,26,521.81as of 12:41 AM IST|
0%
real-estate

NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing

Arth Vani DeskPublished: 2 min read
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing

Source: ET Real Estate

Recommended for you
Check home-loan rates & eligibility
Explore Home Loans
Listen to this article
AI voice · Podcast mode
Get IPO & market alerts free on Telegram / WhatsApp
AI Summary

NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.

Key Highlights
  • ▸NITI Aayog is actively working on new policies to boost local production of medical and dental devices.
  • ▸The government is addressing challenges like complex regulations and cost disadvantages faced by Indian manufacturers.
  • ▸This initiative aims to reduce India's dependence on imported medical equipment.
  • ▸A stronger domestic manufacturing sector could lead to more affordable healthcare products and job creation.
Key Takeaways
  • ✓NITI Aayog is actively working on new policies to boost local production of medical and dental devices.
  • ✓The government is addressing challenges like complex regulations and cost disadvantages faced by Indian manufacturers.
  • ✓This initiative aims to reduce India's dependence on imported medical equipment.
  • ✓A stronger domestic manufacturing sector could lead to more affordable healthcare products and job creation.

NITI Aayog, the premier public policy think tank of the Government of India, is spearheading efforts to bolster the country's medical and dental device manufacturing industry. The organization is currently exploring a range of policy measures designed to improve local production capabilities, ultimately aiming to reduce India's reliance on imports and foster self-sufficiency in this critical sector.

This strategic push comes amidst a growing recognition of the Indian healthcare sector's needs and the potential for domestic manufacturers to meet them. India, currently, depends significantly on imported medical devices, and strengthening local manufacturing is seen as vital for both economic growth and national health security.

A recent high-level meeting convened by NITI Aayog brought together key stakeholders to discuss the path forward. Participants included a diverse group: domestic manufacturers who are at the forefront of the industry, senior government officials involved in policy formulation, and leading experts from prestigious institutions like IIT Delhi and IIT Mumbai. This collaborative approach underscores the comprehensive nature of the policy exploration.

During these extensive discussions, several key challenges hindering the growth of Indian medical and dental device manufacturers were brought to the forefront. Prominent among these were significant regulatory hurdles, which often add complexity and time to product development and market entry. Additionally, Indian manufacturers frequently face cost disadvantages when competing with established international players, impacting their market share and profitability.

The Association of Indian Medical Device Industry (AiMeD), a leading industry body representing local manufacturers, played a crucial role in these discussions. AiMeD emphatically highlighted the urgent need for simpler and more streamlined regulations to ease the operational burden on local companies. Furthermore, the organization advocated for robust financial support mechanisms tailored to the specific needs of Indian manufacturers, which could help them scale up operations, invest in research and development, and become more competitive globally.

For the average Indian citizen, a boost in domestic medical device manufacturing could translate into several benefits. A stronger local industry could lead to more affordable medical equipment and supplies, potentially reducing healthcare costs in the long run. It could also improve the availability and accessibility of essential devices, especially in remote or underserved areas. Moreover, increased manufacturing activity would undoubtedly create new job opportunities across various skill levels within the country, contributing to economic development.

The ongoing policy exploration by NITI Aayog signifies a determined effort to address systemic issues and create a more conducive environment for 'Make in India' in the medical and dental device segment. The outcomes of these discussions are expected to shape future government policies, paving the way for a robust and self-reliant Indian medical device industry capable of serving both domestic and international markets.

This article is for informational purposes only and does not constitute financial or investment advice.

Recommended for you
Products related to this story — compare & act
Smart picks
Nippon India Small Cap Fund
Nippon India Mutual Fund · Small Cap
13.5%
3Y CAGR
Parag Parikh Flexi Cap Fund
PPFAS Mutual Fund · Flexi Cap
12.3%
3Y CAGR
Mirae Asset ELSS Tax Saver Fund
Mirae Asset Mutual Fund · ELSS
11.1%
3Y CAGR
ICICI Prudential Balanced Advantage Fund
ICICI Prudential Mutual Fund · Hybrid
10.4%
3Y CAGR
HDFC Balanced Advantage Fund
HDFC Mutual Fund · Hybrid
10.1%
3Y CAGR
Axis ELSS- Tax Saver Fund
Axis Mutual Fund · ELSS
9.4%
3Y CAGR

Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.

Frequently Asked Questions

What is NITI Aayog doing regarding medical device manufacturing?

NITI Aayog is exploring new policy measures to strengthen India's domestic manufacturing capabilities for medical and dental devices, aiming to foster self-reliance.

Who participated in NITI Aayog's discussions on this topic?

The discussions included domestic manufacturers, senior government officials, and experts from IIT Delhi and IIT Mumbai.

What are the main challenges faced by Indian medical device manufacturers?

Indian manufacturers face significant challenges such as complex regulatory hurdles and cost disadvantages when competing with international players.

Stay ahead of the market

Join the Arth Vani channels

Daily news summaries, IPO & market alerts on Telegram and WhatsApp.

Related Stories

Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
real-estate

Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat

The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.

1d ago·2 min readListen
Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
real-estate

Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement

Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.

1d ago·1 min readListen
Hospitals, Clinics May Soon Prominently Display Service Rates
Breaking
real-estate

Hospitals, Clinics May Soon Prominently Display Service Rates

Health Secretary Punya Salila Srivastava has urged state and UT health authorities to mandate prominent display of service rates by hospitals and clinics. This move aims to help patients and their attendants understand treatment costs, make informed financial decisions, and plan their healthcare spending more effectively.

2d ago·2 min readListen
BR Shetty Sues Bank of Baroda for ₹1.25 Lakh Crore Alleging Fraud & Negligence
Breaking
real-estate

BR Shetty Sues Bank of Baroda for ₹1.25 Lakh Crore Alleging Fraud & Negligence

NMC Healthcare founder BR Shetty has filed a massive $15 billion (approximately ₹1.25 lakh crore) lawsuit against Bank of Baroda in the Bombay High Court. The suit alleges fraud and negligence, seeking damages for direct losses, consequential harm, and reputational damage.

2d ago·1 min readListen